Teriparatide use is associated with increased odds of 2-year implant failure and revision in osteopenic patients undergoing cervical fusion
Teriparatide use in osteopenic patients undergoing cervical fusion is associated with increased risks of 2-year implant failure and surgical revisions. These findings suggest that while teriparatide improves bone quality, its efficacy may be limited in this population. Future research should explore tailored interventions to optimize surgical outcomes in osteopenic patients.
Authors
- Jad Bou Monsef (ORCID: https://orcid.org/0000-0001-5614-3690)
- Mitchell K. Ng (ORCID: https://orcid.org/0000-0002-5831-055X)
- Matthew Johnson (ORCID: https://orcid.org/0000-0002-7999-3273)
- Afshin E. Razi (ORCID: https://orcid.org/0000-0002-3443-4582)
- Ameer Tabbaa
- Paul G. Mastrokostas (ORCID: https://orcid.org/0000-0002-1196-517X)
- Leonidas E. Mastrokostas (ORCID: https://orcid.org/0009-0006-8926-3502)
Institutions
- Maimonides Medical Center (US)
- SUNY Downstate Health Sciences University (US)
Publication Details
- Journal
- Journal of Craniovertebral Junction and Spine
- Published
- 2025-04-01
- DOI
- https://doi.org/10.4103/jcvjs.jcvjs_30_25
- Citations
- 1
- Primary Topic
- Spine and Intervertebral Disc Pathology
- Type
- article
- Field-Weighted Citation Impact
- 1.47